EyePoint Pharmaceuticals, Inc. (EYPT)
NASDAQ: EYPT · Real-Time Price · USD
6.15
-0.20 (-3.15%)
Feb 21, 2025, 4:00 PM EST - Market closed
EyePoint Pharmaceuticals Employees
EyePoint Pharmaceuticals had 121 employees as of December 31, 2023. The number of employees decreased by 23 or -15.97% compared to the previous year.
Employees
121
Change (1Y)
-23
Growth (1Y)
-15.97%
Revenue / Employee
$377,793
Profits / Employee
-$855,950
Market Cap
431.48M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
EYPT News
- 5 days ago - EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 23 days ago - EyePoint: A Risky 'Buy' Ahead Of Key Readout For Long-Acting Eylea Rival - Seeking Alpha
- 23 days ago - EyePoint to Present at Guggenheim SMID Cap Biotech Conference - GlobeNewsWire
- 6 weeks ago - EyePoint Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.D. - GlobeNewsWire
- 2 months ago - EyePoint Announces First Patient Dosed in Second Global Phase 3 LUCIA Clinical Trial of DURAVYU™ for the Treatment of Wet Age-Related Macular Degeneration - GlobeNewsWire
- 3 months ago - EyePoint Pharmaceuticals: Low Price And Good Data Create An Opportunity - Seeking Alpha
- 3 months ago - EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences - GlobeNewsWire
- 4 months ago - EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares - GlobeNewsWire